智通财经APP获悉，康宁杰瑞制药-B(09966)早盘涨超7%，截至发稿，涨5.03%，报3.97港元，成交额1077.95万港元。
消息面上，近日，康宁杰瑞生物制药与石药集团共同宣布，HER2双特异性抗体KN026联合白蛋白结合型多西他赛HB1801的一项Ⅲ期临床研究（研究方案号：KN026-004）申请已获得国家药品监督管理局（NMPA）药品审评中心（CDE）批准，用于HER2阳性早期或局部晚期乳腺癌的新辅助治疗。
值得注意的是，康宁杰瑞上月底发公告称，与石药集团订立许可协议。据此，石药集团获得在内地开发、销售、许诺销售及商业化JSKN003(用于治疗肿瘤相关适应症)的独家许可及再许可权，并成为该地区JSKN003用于该领域的唯一上市许可持有人。公司有权收取最高合共人30.8亿人民币的预付款及里程碑付款。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.